The benefit of bone-seeking radiopharmaceuticals in the treatment of metastatic bone pain

The surface bone-seeking radiopharmaceuticals rhenium-188-HEDP (188Re-HEDP) and samarium-153-EDTMP (153Sm-EDTMP) were investigated to determine the efficacy and toxicity in pain palliation in bone metastases. The effect of treatment with 188Re-HEDP and 153Sm-EDTMP on pain symptoms, life quality, and...

Full description

Saved in:
Bibliographic Details
Published in:Journal of cancer research and clinical oncology 2005-01, Vol.131 (1), p.60-66
Main Authors: Liepe, Knut, Runge, Roswitha, Kotzerke, Jörg
Format: Article
Language:English
Subjects:
Aged
Aged, 80 and over
Analgesics, Non-Narcotic - therapeutic use
Bone Neoplasms - complications
Bone Neoplasms - drug therapy
Bone Neoplasms - secondary
Bones
Breast cancer
Breast Neoplasms - pathology
Chemotherapy
Etidronic Acid - therapeutic use
Female
Humans
Karnofsky Performance Status
Male
Medical treatment
Middle Aged
Organometallic Compounds - therapeutic use
Organophosphorus Compounds - therapeutic use
Pain - drug therapy
Pain - etiology
Pain - prevention & control
Pain management
Palliative Care - methods
Prostatic Neoplasms - pathology
Radioisotopes - therapeutic use
Surveys and Questionnaires
Time Factors
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The surface bone-seeking radiopharmaceuticals rhenium-188-HEDP (188Re-HEDP) and samarium-153-EDTMP (153Sm-EDTMP) were investigated to determine the efficacy and toxicity in pain palliation in bone metastases. The effect of treatment with 188Re-HEDP and 153Sm-EDTMP on pain symptoms, life quality, and bone marrow function were obtained in 46 patients with prostate and breast cancer. There were 31 patients treated with 188Re-HEDP (3194+/-387 MBq) and 15 patients with 153Sm-EDTMP (2940+/-545 MBq). The 188Re-HEDP group included 6 patients and 25 patients, and the 153Sm-EDTMP group 6 patients and 9 patients with breast and prostate cancer, respectively. All patients had an interview using standardized sets of questions before and after therapy for 12 weeks. Blood counts were taken weekly for 6 weeks and after 12 weeks. After treatment with 188Re-HEDP, 77% of patients reported pain relief and 73% after 153Sm-EDTMP. Sixteen percent of the patients treated with 188Re-HEDP and 13% of those given 153Sm-EDTMP could discontinue their analgesics and were pain free. Patients described an improvement on the Karnofsky performance scale from 73+/-7 to 85+/-8% 12 weeks after 188Re-HEDP (p
ISSN:0171-5216
1432-1335
DOI:10.1007/s00432-004-0625-0